Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth

Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adoption of its core endocrinology products. Q4 was particularly significant, as the company achieved an operating profit of €10 million and generated €73 million in operating cash flow. This was largely driven by YORVIPATH, which brought in €477 million for the full year, and the steady performance of SKYTROFA, which contributed €206 million.

Despite a full-year net loss of €228 million due to commercial investments, the company ended the year with a solid cash position of €616 million, supported by a $100 million partnership payment from Novo Nordisk. The company’s success is rooted in its proprietary TransCon tech platform, which transforms established drugs into long-acting, once-weekly prodrugs. By linking parent drugs to an inert carrier via a temporary linker, TransCon ensures a predictable and sustained release of the active medication.

Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth

15 States with the Best Healthcare in the US

This has allowed Ascendis Pharma to secure a dominant 45% share of the US long-acting growth hormone market for SKYTROFA. Management is now preparing for the next major growth phase with the anticipated FDA approval of TransCon CNP for pediatric achondroplasia, which has a PDUFA action date of February 28, 2026, and is expected to provide a new therapeutic option beyond simple linear growth.

Ascendis Pharma is a biopharmaceutical company that develops TransCon-based (Transient Conjugation) therapies for unmet medical needs in Europe, the US, and internationally.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.